HCW Biologics (HCWB) EBIAT (2021 - 2025)
Historic EBIAT for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to -$4.6 million.
- HCW Biologics' EBIAT fell 1670.94% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.1 million, marking a year-over-year increase of 6771.53%. This contributed to the annual value of -$30.0 million for FY2024, which is 2012.28% down from last year.
- According to the latest figures from Q3 2025, HCW Biologics' EBIAT is -$4.6 million, which was down 1670.94% from -$1.9 million recorded in Q2 2025.
- HCW Biologics' 5-year EBIAT high stood at -$1.9 million for Q2 2025, and its period low was -$15.3 million during Q2 2024.
- Over the past 5 years, HCW Biologics' median EBIAT value was -$3.9 million (recorded in 2022), while the average stood at -$4.8 million.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 25498.84% in 2024, then surged by 8738.41% in 2025.
- HCW Biologics' EBIAT (Quarter) stood at -$3.2 million in 2021, then tumbled by 70.75% to -$5.4 million in 2022, then plummeted by 97.1% to -$10.7 million in 2023, then surged by 68.42% to -$3.4 million in 2024, then tumbled by 35.01% to -$4.6 million in 2025.
- Its EBIAT was -$4.6 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$2.2 million in Q1 2025.